utci902

Property	Value
?:abstract	Background/Objective: There is a paucity of data on the management of gastrointestinal (GI) bleeding in patients with Coronavirus disease -2019 (COVID-19) amid concerns about the risk of transmission during endoscopic procedures We aimed to study the outcomes of conservative treatment for GI bleeding in patients with COVID-19 Methods: In this retrospective analysis, 24 of 1342 (1 8%) patients with COVID-19, presenting with GI bleeding from 22nd April to 22nd July 2020, were included Results: The mean age of patients was 45 8 ± 12 7 years;17 (70 8%) were males;upper GI (UGI) bleeding: lower GI (LGI) 23:1 Twenty-two (91 6%) patients had evidence of cirrhosis- 21 presented with UGI bleeding while one had bleeding from hemorrhoids Two patients without cirrhosis were presumed to have non-variceal bleeding The medical therapy for UGI bleeding included vasoconstrictors-somatostatin in 17 (73 9%) and terlipressin in 4 (17 4%) patients All patients with UGI bleeding received proton pump inhibitors and antibiotics Packed red blood cells (PRBCs), fresh frozen plasma (FFPs) and platelets were transfused in 14 (60 9%), 3 (13 0%) and 3 (13 0%), respectively The median PRBCs transfused was 1 (0–3) unit(s) The initial control of UGI bleeding was achieved in all 23 patients and none required an emergency endoscopy At 5-day follow-up, none rebled or died Two patients later rebled, one had intermittent bleed due to gastric antral vascular ectasia, while another had rebleed 19 days after discharge Three (12 5%) cirrhosis patients succumbed to acute hypoxemic respiratory failure during hospital stay Conclusion: Conservative management strategies including pharmacotherapy, restrictive transfusion strategy, and close hemodynamic monitoring can successfully manage GI bleeding in COVID-19 patients and reduce need for urgent endoscopy The decision for proceeding with endoscopy should be taken by a multidisciplinary team after consideration of the patient\'s condition, response to treatment, resources and the risks involved, on a case to case basis
is ?:annotates of	<https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C0003232> <https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C0017181> <https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C0019080> <https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C0042397> <https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C0267211> <https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C0333106> <https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C0358591> <https://research.tib.eu/covid-19/entity/4utci902_hasAnnotation_C1874451>
?:creator	<https://research.tib.eu/covid-19/entity/Shalimar%2C_Vaishnav_M.%3B_Elhence%2C_A.%3B_Kumar%2C_R.%3B_Mohta%2C_S.%3B_Palle%2C_C.%3B_Kumar%2C_P.%3B_Ranjan%2C_M.%3B_Vajpai%2C_T.%3B_Prasad%2C_S.%3B_Yegurla%2C_J.%3B_Dhooria%2C_A.%3B_Banyal%2C_V.%3B_Agarwal%2C_S.%3B_Bansal%2C_R.%3B_Bhattacharjee%2C_S.%3B_Aggarwal%2C_R.%3B_Soni%2C_K._D.%3B_Rudravaram%2C_S.%3B_Singh%2C_A._K.%3B_Altaf%2C_I.%3B_Choudekar%2C_A.%3B_Mahapatra%2C_S._J.%3B_Gunjan%2C_D.%3B_Kedia%2C_S.%3B_Makharia%2C_G.%3B_Trikha%2C_A.%3B_Garg%2C_P.%3B_Saraya%2C_A.>
?:journal	Journal_of_Clinical_and_Experimental_Hepatology
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	WHO
?:title	Outcome of Conservative Therapy in Coronavirus disease-2019 Patients Presenting With Gastrointestinal Bleeding
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#909239
?:year	2020

Property

Value

?:abstract

Background/Objective: There is a paucity of data on the management of gastrointestinal (GI) bleeding in patients with Coronavirus disease -2019 (COVID-19) amid concerns about the risk of transmission during endoscopic procedures We aimed to study the outcomes of conservative treatment for GI bleeding in patients with COVID-19 Methods: In this retrospective analysis, 24 of 1342 (1 8%) patients with COVID-19, presenting with GI bleeding from 22nd April to 22nd July 2020, were included Results: The mean age of patients was 45 8 ± 12 7 years;17 (70 8%) were males;upper GI (UGI) bleeding: lower GI (LGI) 23:1 Twenty-two (91 6%) patients had evidence of cirrhosis- 21 presented with UGI bleeding while one had bleeding from hemorrhoids Two patients without cirrhosis were presumed to have non-variceal bleeding The medical therapy for UGI bleeding included vasoconstrictors-somatostatin in 17 (73 9%) and terlipressin in 4 (17 4%) patients All patients with UGI bleeding received proton pump inhibitors and antibiotics Packed red blood cells (PRBCs), fresh frozen plasma (FFPs) and platelets were transfused in 14 (60 9%), 3 (13 0%) and 3 (13 0%), respectively The median PRBCs transfused was 1 (0–3) unit(s) The initial control of UGI bleeding was achieved in all 23 patients and none required an emergency endoscopy At 5-day follow-up, none rebled or died Two patients later rebled, one had intermittent bleed due to gastric antral vascular ectasia, while another had rebleed 19 days after discharge Three (12 5%) cirrhosis patients succumbed to acute hypoxemic respiratory failure during hospital stay Conclusion: Conservative management strategies including pharmacotherapy, restrictive transfusion strategy, and close hemodynamic monitoring can successfully manage GI bleeding in COVID-19 patients and reduce need for urgent endoscopy The decision for proceeding with endoscopy should be taken by a multidisciplinary team after consideration of the patient\'s condition, response to treatment, resources and the risks involved, on a case to case basis

is ?:annotates of